Press releases
- Newron Presents Six-Month Interim Data From the First 100 Patients Randomized in Study 014/015 at the 31st European Congress of Psychiatry
- Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia
- Newron to present at the 31st European Congress of Psychiatry
- Newron Announces 2022 Financial Results and Provides Outlook For 2023
- Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia
- Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 17.85m |
Free float | 16.96m |
P/E (TTM) | -- |
Market cap | 106.55m CHF |
EPS (TTM) | -0.9774 CHF |
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼